Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's Crinecerfont?
Crinecerfont is a small molecule commercialized by Neurocrine Biosciences, with a leading Pre-Registration program in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)....
Data Insights
Crinecerfont by Neurocrine Biosciences for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome): Likelihood of Approval
Crinecerfont is under clinical development by Neurocrine Biosciences and currently in Pre-Registration for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According to...